Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
KIN's Cash to Debt is ranked higher than
69% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. KIN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KIN' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Interest Coverage No Debt
KIN's Interest Coverage is ranked lower than
65% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KIN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KIN' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
Z-Score: 23.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -26.76
KIN's ROE (%) is ranked higher than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. KIN: -26.76 )
Ranked among companies with meaningful ROE (%) only.
KIN' s 10-Year ROE (%) Range
Min: -33.44  Med: -23.38 Max: -13.32
Current: -26.76
-33.44
-13.32
ROA (%) -26.03
KIN's ROA (%) is ranked higher than
51% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. KIN: -26.03 )
Ranked among companies with meaningful ROA (%) only.
KIN' s 10-Year ROA (%) Range
Min: -32.42  Med: -22.65 Max: -12.87
Current: -26.03
-32.42
-12.87
ROC (Joel Greenblatt) (%) -8951.85
KIN's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. KIN: -8951.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KIN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70316.67  Med: -41865.97 Max: -13415.27
Current: -8951.85
-70316.67
-13415.27
» KIN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

KIN Guru Trades in Q3 2014

Seth Klarman 3,013,848 sh (+9.05%)
» More
Q4 2014

KIN Guru Trades in Q4 2014

Jim Simons 20,400 sh (New)
John Rogers 134,425 sh (New)
Seth Klarman 3,013,848 sh (unchged)
» More
Q1 2015

KIN Guru Trades in Q1 2015

Jim Simons 114,700 sh (+462.25%)
John Rogers 283,600 sh (+110.97%)
Seth Klarman 3,013,848 sh (unchged)
» More
Q2 2015

KIN Guru Trades in Q2 2015

John Rogers 1,212,359 sh (+327.49%)
Jim Simons 177,855 sh (+55.06%)
Seth Klarman 3,013,848 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.32
KIN's P/B is ranked higher than
88% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. KIN: 1.32 )
Ranked among companies with meaningful P/B only.
KIN' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 5.6
Current: 1.32
0
5.6
Current Ratio 31.85
KIN's Current Ratio is ranked higher than
96% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. KIN: 31.85 )
Ranked among companies with meaningful Current Ratio only.
KIN' s 10-Year Current Ratio Range
Min: 10.63  Med: 31.85 Max: 45.03
Current: 31.85
10.63
45.03
Quick Ratio 31.85
KIN's Quick Ratio is ranked higher than
96% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. KIN: 31.85 )
Ranked among companies with meaningful Quick Ratio only.
KIN' s 10-Year Quick Ratio Range
Min: 10.63  Med: 31.85 Max: 45.03
Current: 31.85
10.63
45.03

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.34
KIN's Price/Net Cash is ranked higher than
95% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. KIN: 1.34 )
Ranked among companies with meaningful Price/Net Cash only.
KIN' s 10-Year Price/Net Cash Range
Min: 1.5  Med: 1.75 Max: 5.19
Current: 1.34
1.5
5.19
Price/Net Current Asset Value 1.33
KIN's Price/Net Current Asset Value is ranked higher than
94% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. KIN: 1.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KIN' s 10-Year Price/Net Current Asset Value Range
Min: 1.49  Med: 1.74 Max: 5.15
Current: 1.33
1.49
5.15
Price/Tangible Book 1.33
KIN's Price/Tangible Book is ranked higher than
90% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. KIN: 1.33 )
Ranked among companies with meaningful Price/Tangible Book only.
KIN' s 10-Year Price/Tangible Book Range
Min: 1.48  Med: 1.74 Max: 5.15
Current: 1.33
1.48
5.15
Earnings Yield (Greenblatt) (%) -103.78
KIN's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. KIN: -103.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KIN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -177.01  Med: 0.00 Max: 0
Current: -103.78
-177.01
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1 9
EPS($) -1.54 -1.80 -1.60
EPS without NRI($) -1.54 -1.80 -1.60

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:17K.Germany,
» More Articles for KIN

Headlines

Articles On GuruFocus.com
Seth Klarman Nearly Doubles Stake in Atara Biotherapeutics Apr 15 2015 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 

More From Other Websites
KINDRED BIOSCIENCES, INC. Financials Aug 22 2015
Kindred Bio reports 2Q loss Aug 10 2015
Kindred Bio reports 2Q loss Aug 10 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 10 2015
Kindred Biosciences Announces Second Quarter 2015 Financial Results Aug 10 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 05 2015
KindredBio Announces Appointment of Jennifer Elliott as Vice President of Legal Affairs and... May 28 2015
Why the Earnings Streak Will Continue for Kindred Biosciences (KIN) - Tale of the Tape May 20 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 08 2015
Kindred Bio reports 1Q loss May 08 2015
Kindred Bio reports 1Q loss May 08 2015
Kindred Biosciences Announces First Quarter 2015 Financial Results May 08 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 24 2015
Kindred Biosciences to Present at 2015 Jefferies Animal Health Summit Mar 19 2015
Kindred Biosciences Announces Positive Results of Pilot Field Study of KIND-012 for the Control of... Mar 16 2015
KINDRED BIOSCIENCES, INC. Files SEC form 10-K, Annual Report Mar 13 2015
Kindred Bio reports 4Q loss Mar 12 2015
Kindred Bio reports 4Q loss Mar 12 2015
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 12 2015
Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results Mar 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK